After topical application, diclofenac penetrates through the skin and into the tissues beneath.8 It is retained in the muscle and other tissues that are often the source of pain.8,9
When it comes to topical NSAIDs, formulation can be more important than concentration.10 The Emulgel formulation possesses the advantages of both gels and emulsions, favouring rapid absorption, ease of application and good acceptability to patients.7,11,12
Voltaren Emulgel penetrates through the skin to a depth of up to 1 cm, enabling targeted action against pain and inflammation.4,5
Effective relief of pain and reduction of inflammation1–3
In a randomised, double-blind, placebo-controlled study of patients with acute neck pain, Voltaren Emulgel delivered significantly greater reduction in pain-on-movement and pain-at-rest – over three times that of placebo. Additionally, recovery time was about twice as fast as placebo.1*†
*Recovery time was defined as a clinically relevant decrease in pain plus an increase in neck function.††72 patients with acute neck pain received 2 g Voltaren (1%) Emulgel four times daily or placebo for 5 days.
The lowest number-needed-to-treat (NNT) vs other topical NSAIDs in acute musculoskeletal pain3,13
A Cochrane Review comparing topical NSAIDs and placebo showed favourable efficacy for Voltaren Emulgel*† vs other treatments. Of all topical NSAIDs tested for treatment of acute musculoskeletal pain, Voltaren Emulgel had the lowest NNT.3,13‡ with pain relief reported as similar to oral NSAIDs.
This means that for every single patient you treat with Voltaren Emulgel over other topical NSAIDs, you have a better chance of giving them the significant pain relief that helps get them back on their feet and enjoying life again.3
*1% and 2% Voltaren Emulgel formulations included in the review.†For treatment of strains, sprains or sports or overuse-type injuries.‡vs topical ibuprofen, ketoprofen, benzydamine, piroxicam and indomethacin.
20 g, 50 g 100 g. Voltaren Emulgel. Each 100 g of gel contains 1,16 g
Diclofenac diethylammonium corresponding to 1 g diclofenac sodium. Reg.No.: U/3.1/77. Indicated for use in adults and adolescents older than 12 years. Safety in pregnancy and lactation has not been established. Consult your pharmacist/ healthcare professional if needed. GlaxoSmithKline Consumer Healthcare South Africa (Pty) Ltd. 39 Hawkins Avenue, Epping Industria 1, Cape Town, 7460. Reg. No: 2014/173930/07. For full prescribing information refer to the professional information approved by the medicines regulatory authority. For any further information, including safety, please contact the GSK Hotline on +27 11 745 6001 or 0800118274. Trademarks are owned by or licensed to GSK group of companies.Promotion Number:
Voltaren Emulgel has a reduced systemic side-effect risk vs oral NSAIDs’15,16
The low systemic absorption of Voltaren Emulgel means that it has a reduced risk of systemic side effects.8,15,16*
*There is an increased risk of mild dermatological side effects (e.g. skin irritation) with topical diclofenac, but this is non-serious and reversible.
First-line medication use
To improve pain, inflammation and recovery after sprains and strains, guidance from the National Institute for Health and Care Excellence (NICE) recommends using topical NSAIDs or paracetamol as initial analgesics for soft-tissue injuries.17
Patients should also be advised not to apply heat to the injury during the first 72 hours.17
Ben wants effective pain relief and fast recovery
Ben balances the demands of his full-time job with taking care of two young children.
He enjoys going to the gym or exercising outdoors and loves nothing more than playing with his children.
The last thing he needs is pain affecting his life.
Voltaren Emulgel speeds up recovery by relieving pain and reducing inflammation,1 so Ben can get back on with his life.
Recommend Voltaren Emulgel to your patients for reduction of muscle pain and inflammation
For patients who are looking for relief of localized traumatic inflammation and pain, using a topical formulation.
1 g of Voltaren Triple Effect 1.16% Emulgel contains 11.6 mg of diclofenac diethylamine, which corresponds to 10 mg of diclofenac sodium.
Also contains excipients (carbomer, macrogol cetostearyl ether, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, propylene glycol, liquid paraffin, perfume cream 45 (containing benzyl benzoate) purified water).
The duration of treatment depends on the indication and the response obtained. It is recommended that treatment be reviewed after 2 weeks.
Adults and adolescents aged 12 and over Voltaren Emulgel should be applied over the affected area three or four times daily and rubbed gently into the skin. The amount needed depends on the size of the painful area: 2 g to 4 g (cherry to walnut sized) is sufficient to treat an area of about 400–800 cm. After application, the hands should be washed, unless they are the site being treated.
The likelihood of systemic side effects with topical diclofenac is less than that seen in patients using oral diclofenac. However, when Voltaren Emulgel is applied to relatively large areas of the skin, the possibility of systemic side effects cannot be excluded.
Voltaren Emulgel contains propylene glycol, which may cause mild, localised skin irritation in some people.
Voltaren Emulgel should be applied only to intact skin surfaces, and not to skin wounds or open injuries. It should not be allowed to come into contact with the eyes or mucous membranes.
Not to be taken by mouth.
Voltaren Emulgel should be used with caution in asthmatic patients in whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or by other medicines with prostaglandin-synthetase inhibiting activity.
- Known hypersensitivity to diclofenac, acetylsalicylic acid and other non-steriodal anti-inflammatory drugs, as well as to isopropanol or propylene glycol.
- Patients with porphyria
- During the last trimester of pregnancy
The following convention has been utilised for the classification of undesirable effects: very common (≥ 1/10) common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000):
Infection and infestation
Immune system disorders
Respiratory, thoracic and mediastinal disorders
Skin and subcutaneous tissue disorders
Dermatitis bullous Frequent bullous dermatitis Rare Photosensitivity reaction Common
For full prescribing information refer to the professional information approved by the medicines regulatory authority.